Midhun Malla, MD

Midhun Malla, MD of University of Alabama at Birmingham.

Articles by Midhun Malla, MD

Chandler Park, MD, medical oncologist, Norton Cancer Institute; Midhun Malla, MD, the University of Alabama at Birmingham

Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD

ByChandler Park, MD, MSc, FACP,Midhun Malla, MD

July 2nd 2025

Drs Park and Malla discuss therapeutic options for patients with metastatic colorectal cancer, particularly in the third-line setting and beyond.

BRAF-Mutant and HER2+ mCRC Management Strategies Are Becoming Increasingly Tailored: With Chandler Park, MD, and Midhun Malla, MD

ByChandler Park, MD, MSc, FACP,Midhun Malla, MD

June 26th 2025

Chandler Park, MD and Midhun Malla, MD discuss treatment personalization in mCRC, with a focus on BRAF V600E–mutant tumors and HER2-altered disease.

Evolving Molecular Profiling and Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: With Chandler Park, MD; and Midhun Malla, MD

ByChandler Park, MD, MSc, FACP,Midhun Malla, MD

May 29th 2025

Park and Malla discuss evolving approaches to colorectal cancer (CRC) management, with a focus on ctDNA, adjuvant therapy decision-making, and molecular profiling in metastatic disease.

Midhun Malla, MD

Articles by Midhun Malla, MD

Biomarker-Directed Therapies Improve Outlooks for the mCRC Treatment Arsenal: With Chandler Park, MD; and Midhun Malla, MD

BRAF-Mutant and HER2+ mCRC Management Strategies Are Becoming Increasingly Tailored: With Chandler Park, MD, and Midhun Malla, MD

Evolving Molecular Profiling and Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: With Chandler Park, MD; and Midhun Malla, MD

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma